Women's
Health

Perimenopause & Menopause

Perimenopause — the transition phase before the final menstrual period — typically begins in the mid-40s and lasts 4–8 years. It's not a single event. It's a decade-long biological recalibration: fluctuating estrogen, rising FSH, declining progesterone, and a cascade of downstream effects on metabolism, sleep, cardiovascular health, and bone density. According to the [NAMS], more than half of women experience meaningful vasomotor, psychological, or urogenital symptoms during this transition.

The standard framing — "it's a natural process" — is correct in the sense that it is natural. It's not particularly helpful as a management framework. Estrogen decline drives insulin resistance. Progesterone decline disrupts sleep architecture. The interaction between these two shifts is what creates the well-documented perimenopause weight gain pattern — and it's not a calorie failure. Understanding the mechanism is the prerequisite to working with it. The first thing to know: perimenopause and menopause are not one transition but several overlapping ones, each with its own timeline and its own levers.

• → Perimenopause Symptom Checker — 12 questions scoring symptoms across 12 body systems
• → Best Perimenopause Supplements for Weight Loss — 6 evidence-graded options targeting the hormonal drivers

Thyroid Health

Thyroid disorders are not an equal-opportunity condition. Women develop autoimmune thyroid disease at 4–6 times the rate of men,[1] driven by the interaction between female sex hormones, X-chromosome gene dosage, and immune regulation. Hashimoto's thyroiditis — the most common cause of hypothyroidism — typically develops between ages 30 and 50, which means it often emerges alongside the earliest hormonal shifts of perimenopause. Studies show 8–10% of perimenopausal women have thyroid dysfunction — rising to 14–20% after 60.

The clinical problem is overlap. Fatigue, weight gain, mood changes, and menstrual irregularity are symptoms shared by thyroid dysfunction and perimenopause. The only way to distinguish them is with a blood panel including TSH, Free T4, and anti-TPO antibodies — not a symptom checklist, and not a guess. Before attributing midlife symptoms to "just hormones," a thyroid panel is the appropriate first step. The two conditions can co-exist; ruling one out doesn't confirm the other.

• → Thyroid Symptom Checker — 20 questions mapped to hypothyroid, hyperthyroid, Hashimoto's, and Graves' patterns with a lab guide for your GP

ADHD in Women

ADHD is not a childhood condition that adults outgrow, and it is not a condition that primarily affects hyperactive boys — even though the diagnostic criteria were built almost entirely from studies of hyperactive boys. Women with ADHD more commonly present with inattentiveness, internal restlessness, emotional dysregulation, and rejection sensitivity. These are the quieter presentations that don't fit the disruptive-classroom archetype, and they're the presentations that get misdiagnosed as anxiety, depression, or "just stress" for decades.

The estrogen connection is central: estrogen boosts dopamine production and receptor sensitivity, which partially compensates for ADHD's dopamine regulation deficit. As estrogen declines in perimenopause, that compensation disappears — and many women encounter their most acute ADHD symptoms for the first time in their 40s. A [2025 population-based study] found that 54% of women with ADHD reported debilitating perimenopausal symptoms, compared to one-third of women without ADHD — and their perimenopause began up to 10 years earlier. The two conditions don't just overlap; they amplify each other.

• → ADHD Quiz for Women — 18 questions across 5 dimensions built for how ADHD actually presents in women, not adapted from male research

Hormonal Health & PCOS

Polycystic ovary syndrome affects approximately 1 in 10 women of reproductive age, making it the most common endocrine disorder in that age group. The name is a misdirection: the cysts are a consequence, not a cause. In 70–80% of cases, PCOS is driven by insulin resistance, which elevates LH secretion, which drives androgen production, which disrupts ovulation. It's a metabolic condition with reproductive consequences — not a reproductive condition that happens to affect metabolism.

This distinction matters for treatment. Insulin-focused interventions — reduced carbohydrate load, resistance training, and where appropriate, insulin-sensitising medications — address the root cause. The standard "lose weight and eat less" advice addresses one downstream variable without explaining the mechanism driving it. GLP-1 receptor agonists are showing meaningful evidence for PCOS specifically because they target the insulin pathway, not the symptoms.

• → Best GLP-1 for PCOS — evidence overview of semaglutide and tirzepatide for PCOS [off-label use; consult your clinician before starting]
• → GLP-1 Patches for Women: Do They Work? — why no FDA-approved transdermal GLP-1 exists and what the molecular physics explains
• → GLP-1 While Breastfeeding: Is It Safe? — what zero human breast milk studies means for nursing mothers [generally not recommended; discuss with your doctor]

Bone & Muscle Strength

Peak bone mass is established in the late 20s. From the mid-30s, the balance tilts toward net bone resorption — and that process accelerates sharply in the 5–7 years following menopause, when estrogen's protective effect on bone-forming osteoblasts withdraws. Women can lose up to 20% of their bone density in those years, silently, until a fracture makes the loss visible. By the time osteoporosis is diagnosed on a DEXA scan, the structural deficit has often been building for a decade.

Resistance training is the most evidence-robust tool for preserving bone density: mechanical loading signals osteoblasts to deposit new bone tissue. Walking does not produce sufficient mechanical stress. "Drink milk" addresses only one mineral without the stimulus that tells the body to use it. The sequence is: resistance training provides the signal; adequate protein (at least 1.2g/kg/day), calcium, and vitamin D provide the substrate. Remove either and the system underperforms. Muscle mass matters independently — sarcopenia accelerates after menopause and is directly predictive of insulin resistance, fall risk, and all-cause mortality in older women.

• → Articles on resistance training for women and post-menopause bone health are in development.

Gut Health & the Estrobolome

Estrogen doesn't just circulate freely — it's metabolised, conjugated, excreted, and in many cases reabsorbed, depending on what's happening in the gut. The estrobolome is the subset of gut bacteria involved in this process. These microbes produce beta-glucuronidase, an enzyme that deconjugates estrogen and allows it to re-enter circulation rather than be excreted. An overactive estrobolome drives estrogen dominance; a depleted one accelerates estrogen clearance. Either way, gut bacterial composition has a direct effect on circulating estrogen levels — and by extension, on menstrual regularity, PMS severity, perimenopause symptoms, and risk of hormone-sensitive cancers.

Most probiotic advice for women is brand-specific or generic. The relevant questions are which strains have demonstrated estrobolome activity or vaginal microbiome effects in actual trials — and whether the product's delivery system keeps the bacteria alive long enough to reach the relevant site. CFU count alone is not the answer. Strain specificity and survivability are the variables that matter, and most products that mention the estrobolome don't disclose either.

• → Best Probiotic for Women — strain evidence, estrobolome science, and honest selection criteria

Where to Start

If you're new to this hub and not sure which section applies, three questions narrow it down quickly:

Frequently Asked Questions